Anshika Jain
Rare diseases present one of the most difficult challenges in modern medicine. Individually, each rare condition may affect relatively few people, but collectively, rare diseases affect hundreds of millions of people worldwide. More than 7,000 rare diseases have been identified, and many patients experience years of uncertainty before receiving an accurate diagnosis. The difficulty is not always a lack of medical knowledge. In many cases, the problem is that the information needed to recognise a disease is scattered across symptoms, laboratory results, imaging findings, family history, clinical notes and genetic data that may never have been considered together.
This creates what is often described as a diagnostic odyssey. A patient may visit multiple specialists, undergo repeated tests and receive different possible explanations before a rare condition is identified. Physicians are trained to recognise patterns, but rare diseases can produce unusual combinations of symptoms that an individual doctor may encounter only once or twice during an entire career.
Machine learning offers a different way of approaching this problem. Instead of relying exclusively on a clinician remembering a rare combination of findings, algorithms can analyse large collections of medical information and search for relationships across symptoms, diagnoses, laboratory measurements, clinical narratives, imaging and genetic information. The goal is not to replace physicians but to provide another layer of pattern recognition that can help bring uncommon possibilities into consideration.
Recent research suggests that this field is moving beyond simple symptom-matching. New systems are beginning to integrate electronic health records, phenotype information, genetic results and medical literature, creating increasingly sophisticated approaches to rare-disease diagnosis. At the same time, researchers continue to emphasise that technical performance does not automatically translate into safe or effective clinical care.
Why Rare Diseases Are So Difficult to Diagnose
The central difficulty of rare-disease diagnosis is that rarity changes the meaning of individual symptoms. Fatigue, developmental delay, muscle weakness, seizures, abnormal laboratory results or recurring infections can occur in many common conditions. A physician therefore has to determine whether the combination of findings points toward something much less common.
The problem becomes more complicated when symptoms appear at different stages of a patient’s life. One clue may have been recorded during childhood, another several years later, and a third may appear in a specialist’s clinical note. The connections between these observations may not be obvious when each medical encounter is considered separately.
Electronic health records contain enormous amounts of such information, but traditional healthcare databases are not always designed to represent rare diseases effectively. A recent 2026 study on rare-disease mining noted that many rare-disease concepts do not map cleanly onto conventional coding systems, meaning that patients may remain difficult to identify computationally even when relevant information exists in their records.
Machine learning can potentially address part of this fragmentation by treating the patient’s medical history as a connected information system rather than a collection of isolated encounters.
From Individual Symptoms to Patterns of Symptoms
Traditional diagnostic thinking often begins with a patient’s most prominent symptom and gradually narrows the possibilities. Machine learning can approach the same problem from another direction.
An algorithm can examine combinations of features across large datasets and identify relationships that may be difficult to recognise through individual observation. For example, a combination of developmental characteristics, unusual laboratory values, recurring respiratory problems and a particular imaging finding may be weak evidence individually but become more informative when considered together.
This is particularly relevant to rare diseases because their diagnostic signatures may be distributed across multiple clinical domains. A condition may not have one distinctive symptom. Instead, it may produce a particular pattern involving age of onset, progression, organ involvement, laboratory measurements, imaging characteristics and genetic variants.
Machine learning systems can be trained to recognise these multidimensional patterns. Rather than asking only whether a patient has symptom A, the system can estimate how a large collection of observations relates to different diagnostic possibilities.
This does not mean that an algorithm automatically discovers the correct diagnosis. Instead, it can generate a ranked set of possibilities that a clinician can investigate further.
Electronic Health Records as a Source of Hidden Diagnostic Clues
Electronic health records are becoming increasingly important in machine-learning research because they contain longitudinal information about patients. Diagnoses, laboratory tests, medications, procedures, hospital visits and clinical notes can collectively create a much richer representation of a patient’s medical history than any single consultation.
Modern AI systems are increasingly capable of processing both structured and unstructured information. Structured information includes laboratory measurements and diagnostic codes, while unstructured information includes physician notes, referral letters and narrative descriptions.
A 2026 review in Nature Reviews Genetics highlighted the growing potential of integrating genomic information with electronic health records. Machine-learning methods can help handle high-dimensional, noisy and irregularly timed data, creating opportunities to study disease heterogeneity and improve clinical decision-making.
For rare diseases, this capability could be especially valuable. A pattern that is almost invisible within one patient’s medical record may become meaningful when compared with thousands or millions of other records.
The Importance of Phenotypes
One of the most important concepts in rare-disease machine learning is the phenotype. A phenotype refers broadly to the observable characteristics associated with a person, including symptoms, physical findings, laboratory abnormalities and other clinical features.
Rare-disease research increasingly uses structured phenotype representations such as the Human Phenotype Ontology. These systems provide a way of describing clinical features using standardised concepts, allowing computers to compare patient characteristics with disease characteristics.
This creates a bridge between human clinical language and computational analysis. A physician might describe a patient as having an unusual pattern of developmental delay and muscle weakness, while a computational system can represent those findings as structured phenotype information and compare them against known disease profiles.
The approach becomes more powerful when phenotypes are combined with genetic information. Instead of treating symptoms and DNA findings as separate streams, machine-learning systems can attempt to determine whether a patient’s clinical characteristics are biologically consistent with particular genetic variants or disease mechanisms.
Connecting Clinical Data With Genomic Information
Genomic sequencing has transformed the investigation of rare diseases, but sequencing alone does not necessarily produce an immediate diagnosis. Modern sequencing can identify large numbers of genetic variants, and the difficult task is determining which variants are actually responsible for the patient’s condition.
A 2026 study describing aiDIVA, a hybrid AI system for rare-disease diagnosis, highlighted this challenge. Although genome sequencing makes variant detection increasingly scalable, variant prioritisation and clinical interpretation remain demanding tasks that often require specialist expertise. The system combines evidence-based approaches, machine learning and language-model capabilities to assist this process.
This illustrates an important direction for machine learning in rare diseases. The future may not depend on a single algorithm looking at symptoms. Instead, diagnostic systems may combine clinical phenotypes, genomic variants, laboratory data, medical literature and patient histories into a unified reasoning environment.
The result could be a more comprehensive computational representation of the patient.
When Algorithms Search Medical Literature
Rare diseases create another problem: the relevant knowledge may exist, but it may be distributed across thousands of scientific papers, case reports and specialised databases.
A physician cannot realistically remember every rare disease, every associated phenotype and every newly reported genetic variant. Even specialists have limits on the amount of information they can continuously retain.
AI systems can potentially function as knowledge-retrieval partners. They can search medical literature and structured databases while comparing the retrieved information with the characteristics of an individual patient.
This approach is becoming visible in newer diagnostic architectures. The DeepRare system described in Nature in 2026 integrates clinical information, phenotype terms, genetic testing results and specialised knowledge sources to produce ranked diagnostic hypotheses with traceable reasoning and supporting evidence. The system was evaluated across thousands of diseases and multiple datasets and medical specialties.
The significance of such systems is not simply that they can produce a diagnosis. Their greater potential lies in connecting otherwise disconnected pieces of medical knowledge.
From Machine Learning to Multimodal AI
Earlier generations of machine-learning systems often focused on one type of data. A model might analyse medical images, laboratory values or structured clinical records separately.
Rare diseases increasingly require something more comprehensive.
A patient may have genetic information, clinical notes, photographs, radiology images, laboratory measurements and longitudinal medical history. The diagnostic signal may exist across all of these modalities.
Multimodal AI attempts to combine different types of information into a common computational framework. This could allow an algorithm to consider relationships between a patient’s phenotype and genomic findings while also examining imaging or narrative descriptions.
A 2026 scoping review of AI for pediatric rare diseases found that classical machine learning remained the largest technology category among reviewed studies, followed by facial AI, deep learning, large language models and multimodal AI. However, the review also found that most research remained retrospective and internally validated, with relatively limited prospective and external validation.
This distinction is important. Combining more types of data may make AI systems more powerful, but it also makes validation, interpretability, privacy and clinical governance more complicated.
Can Machine Learning Recognise What Physicians Rarely See?
The central promise of machine learning in rare diseases is pattern recognition at a scale that individual clinicians cannot easily reproduce.
A physician may encounter a particular rare disorder only a few times. An algorithm can potentially learn from thousands of cases, including historical records and published clinical evidence. It can therefore compare a new patient against a much broader reference population.
This is especially valuable when symptoms are distributed across multiple systems. A physician may initially see neurological symptoms, while another specialist may focus on gastrointestinal or metabolic findings. Machine learning can potentially treat these observations as part of one connected pattern.
However, algorithms do not automatically understand medicine in the same way physicians do. Their performance depends heavily on the quality, diversity and representativeness of their training data. If a dataset contains incomplete records, coding errors or underrepresentation of particular populations, the resulting model may reproduce those limitations.
The real question is therefore not whether machines can see patterns that physicians cannot. It is whether machine intelligence can provide additional pattern-recognition capacity while remaining clinically reliable and transparent.
Why Explainability Matters
Rare-disease diagnosis is an area in which simply producing a prediction may not be enough.
If an algorithm suggests that a patient may have an extremely rare genetic disorder, clinicians need to understand why that possibility was generated. Was the recommendation based on developmental history, a specific laboratory result, a genetic variant, an imaging finding or a combination of several factors?
Explainability becomes particularly important when the recommended diagnosis could lead to genetic testing, specialist referral or significant changes in treatment.
Newer systems are therefore increasingly designed to provide evidence supporting their conclusions. Traceable reasoning can allow clinicians to inspect the information behind an algorithmic suggestion rather than treating the model as an unexplained oracle.
This approach could also improve trust. A physician may be more willing to investigate an unusual diagnostic possibility when the system can identify the clinical evidence that led to that recommendation.
The Limits of Current AI Evidence
The enthusiasm surrounding AI in rare-disease diagnosis needs to be balanced against the current evidence.
A systematic review and meta-analysis published in npj Digital Medicine in August 2026 evaluated large language model systems for rare-disease diagnosis. Across 15 studies and 19 system-dataset entries involving 39,529 cases, the pooled proportion of cases where the correct diagnosis was ranked first was 43.3%. Systems augmented with retrieval, agent-based reasoning or fine-tuning performed better on average than standalone models, but substantial heterogeneity remained.
Another 2026 benchmarking study found that large language models had not yet reached the diagnostic accuracy of established rare-disease decision-support tools.
These findings highlight an important principle: impressive AI demonstrations do not automatically mean that a system is ready for routine clinical diagnosis.
Clinical deployment requires external validation, prospective testing, appropriate reference standards, monitoring and evidence that the technology actually improves patient outcomes.
The Problem of Rare-Disease Data
Machine learning generally benefits from large amounts of high-quality data. Rare diseases create an obvious tension because the diseases themselves are uncommon.
A common condition may generate millions of clinical records, while a very rare condition may have only a small number of well-documented cases. This creates class-imbalance problems, where the algorithm sees vastly more examples of common conditions than rare ones.
Researchers are exploring several approaches to address this challenge, including weak supervision, transfer learning, synthetic data, knowledge graphs, federated learning and multimodal learning.
A 2026 study of a weakly supervised transformer for rare-disease diagnosis and subphenotyping demonstrated another approach: using large-scale electronic health-record information to identify disease patterns even when perfectly labelled training data are difficult to obtain.
The challenge remains substantial, but it illustrates how machine learning research is adapting to the special characteristics of rare diseases rather than simply applying conventional diagnostic models.
Machine Learning Should Support Physicians, Not Replace Them
The most realistic future for machine learning in rare-disease diagnosis is likely to involve collaboration between algorithms and clinicians.
A physician provides clinical judgment, contextual understanding, communication with the patient and responsibility for decisions. An algorithm can provide large-scale pattern recognition, information retrieval and comparison against enormous collections of medical data.
The two capabilities are complementary.
An AI system might identify a rare disease as a possibility that a clinician had not initially considered. The physician can then review the evidence, examine the patient again, request appropriate testing and determine whether the proposed diagnosis makes clinical sense.
This human-machine partnership can also reduce one of the risks of automated diagnosis: overreliance on algorithmic recommendations. A machine-generated suggestion should be treated as evidence to evaluate rather than an unquestionable conclusion.
Toward Faster and More Personalised Rare-Disease Diagnosis
The long-term potential of machine learning extends beyond identifying a diagnosis. Once a patient’s phenotype and genetic information are computationally connected, the same infrastructure could support treatment selection, clinical-trial matching, prognosis and longitudinal monitoring.
AI could potentially identify patients who might benefit from specific genetic tests or specialist referrals. It could connect individuals with relevant clinical trials or emerging therapies. It could also monitor longitudinal changes and identify patterns that suggest disease progression.
Recent research increasingly describes rare-disease AI as an integrated diagnostic and care ecosystem rather than a single prediction tool. This reflects the broader movement toward precision medicine, where treatment decisions are informed by increasingly detailed biological and clinical information.
Such systems could eventually transform the diagnostic journey from a fragmented sequence of appointments into a more connected process.
Privacy, Bias and Clinical Responsibility
The expansion of AI in rare diseases also raises significant ethical and practical questions. Rare-disease patients can be particularly identifiable because unusual combinations of genetic and clinical characteristics may make individual records easier to distinguish.
Protecting patient privacy therefore becomes essential when combining genomic data with electronic health records and other sources of information.
Bias is another concern. If an algorithm is trained primarily on patients from a limited geographic, demographic or healthcare setting, its predictions may not generalise to other populations.
Clinical responsibility must also remain clear. If an AI system suggests a diagnosis that turns out to be incorrect, healthcare organisations need transparent processes for determining how the recommendation was generated and how clinicians were expected to use it.
These questions cannot be solved solely through better algorithms. They require governance, clinical validation, data standards and responsible implementation.
The Future of Rare-Disease Diagnosis
The future of rare-disease diagnosis may increasingly involve systems that continuously connect information rather than waiting for a clinician to recognise a rare pattern manually.
Imagine a patient whose medical history contains years of seemingly unrelated observations. A computational system could analyse the longitudinal record, convert clinical descriptions into structured phenotypes, compare those features with known disorders, examine genetic findings and retrieve relevant medical literature. Instead of replacing the physician, it could present a small set of evidence-supported diagnostic possibilities that deserve closer investigation.
That vision is already beginning to emerge in research. Hybrid AI systems, multimodal models, EHR-based machine learning and agentic diagnostic systems are all moving toward more connected forms of computational medicine.
The remaining challenge is translating promising research into reliable clinical practice.
Conclusion
Machine learning could become an important tool for solving one of medicine’s most persistent problems: recognising rare diseases when their symptoms appear fragmented, unfamiliar or spread across years of clinical history.
Its greatest advantage may not be that algorithms know more medicine than physicians. Rather, it is that computational systems can compare enormous quantities of information and search for relationships that are difficult for any individual clinician to remember or recognise.
The emerging generation of rare-disease AI is moving beyond simple symptom matching toward the integration of electronic health records, phenotypes, genomic information, medical literature and multimodal clinical data. Recent systems such as DeepRare and aiDIVA demonstrate how researchers are attempting to create evidence-supported diagnostic reasoning rather than simple black-box predictions.
Yet machine learning is not a substitute for clinical expertise. Current research still shows substantial variation in performance, limited prospective validation and important challenges involving data quality, bias, explainability and patient privacy.
The most valuable future may therefore be collaborative. A physician brings experience, clinical judgment and human understanding, while machine learning brings large-scale pattern recognition and the ability to connect information across enormous medical knowledge bases.
For patients living through a diagnostic odyssey, that combination could eventually mean something profoundly important: fewer disconnected clues, faster recognition of unusual disease patterns and a healthcare system increasingly capable of seeing the whole patient rather than isolated symptoms.